Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
Fakhouri, Fadi; Hourmant, Maryvonne; Campistol, Josep M; Cataland, Spero R; Espinosa, Mario; Gaber, A Osama; Menne, Jan; Minetti, Enrico E; Provôt, François; Rondeau, Eric; Ruggenenti, Piero; Weekers, Laurent E; Ogawa, Masayo; Bedrosian, Camille L; Legendre, Christophe M.
Am J Kidney Dis
; 68(1): 84-93, 2016 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-27012908
Síndrome hemolítico urémico atípico en tratamiento con eculizumab. Casos clínicos.
Atypical hemolytic uremic syndrome: from diagnosis to treatment.
Subclinical atypical haemolytic uremic syndrome relapse following discontinuation of eculizumab.
Absence of thrombocytopaenia and/or microangiopathic haemolytic anaemia does not reliably exclude recurrence of atypical haemolytic uraemic syndrome after kidney transplantation.
Neonatal atypical hemolytic uremic syndrome from a factor H mutation treated with eculizumab.
Atypical hemolytic-uremic syndrome.
Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab.
Evaluation of health-related quality of life in hemolytic uraemic syndrome patients treated with eculizumab: a systematic evaluation on basis of EMPRO.
Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.
Disease Recurrence After Early Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome With Complement C3 I1157T Mutation.